Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flublok + Nuvaxovid
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Flublok + Nuvaxovid is a combination vaccine under development, combining Sanofi's Flublok, a recombinant influenza vaccine, with Novavax's Nuvaxovid, a protein-based COVID-19 vaccine. Nuvaxovid utilizes Novavax's proprietary Matrix-M adjuvant technology to enhance the immune response. This combination aims to provide protection against both influenza and COVID-19. Sanofi has licensed the rights to co-commercialize Nuvaxovid and to develop and commercialize new combination vaccines using Novavax's Matrix-M adjuvant technology.
- Other names
- RIV + rC19Sanofi-Novavax COVID-19-Influenza Combination VaccineSanofi-Novavax CIC
02
Targets
HA0 (Influenza B virus hemagglutinin)SARS-CoV-2 spikeHA (Hemagglutinin)
Beyond the preview
Go deeper on Flublok + Nuvaxovid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flublok + Nuvaxovid.